enGene Therapeutics Inc. ENGNW

Full chart Compare
Set alert

Price alert · ENGNW

All alert types
0.18 USD 0.00 (+0.00%)

Oct 28, 2026, 1:18 PM EDT

0.1813 Day range 0.1831
0.1813 52-week range 0.1831
YTD
0.00%
1 year
0.00%
Market cap
9.28M
YTD return
0.00%
1-year return
0.00%
Open
2.10
Previous close
0.1813
Day's range
0.1813 – 0.1831
52-week range
0.1813 – 0.1831
Beta
-0.76

2Y 0.0000 (0.00%)

No chart data for this range yet.

Key statistics

Enterprise value
0
PEG ratio
0.00
Price / sales
0.00
Price / book
0.19
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
-23.58M
Total cash
257.68M
Total debt
24.86M
Return on equity
-123.06%
Short % of float
0.00%
50-day average
0.00
200-day average
0.00

Next earnings

Consensus EPS estimate 0.00.

Earnings history

About enGene Therapeutics Inc.

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). The company is based in Montreal, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada
Website
engene.com

News

Your note

Sign in to keep a note on ENGNW — it syncs with the Stock Master app.

Institution ownership

ENGNW institution ownership
Holder% heldSharesValueReported
Fcpm III Services B.v. 27.64%2,878,1482.79MSep 29, 2024
BVF Inc.9.08%945,402917.04KSep 29, 2024
Blue Owl Capital Holdings LP4.91%511,177495.84KSep 29, 2024
Omega Fund Management, Llc3.09%321,502311.86KSep 29, 2024
Saba Capital Management, L.P.1.85%192,334186.56KSep 29, 2024
Calamos Advisors LLC1.44%150,000145.50KSep 29, 2024

Fund ownership

ENGNW fund ownership
Holder% heldSharesValueReported
Saba Capital Income & Opportunities Fd0.06%6,0445.86KJul 30, 2024